|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qu S, Wang K, Xue H and Wang Y, Wu R, Liu
C, Gao AC, Gout PW, Collins CC and Wang Y: Enhanced anticancer
activity of a combination of docetaxel and Aneustat (OMN54) in a
patient-derived, advanced prostate cancer tissue xenograft model.
Mol Oncol. 8:311–322. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xing N, Chen Y, Mitchell SH and Young CY:
Quercetin inhibits the expression and function of the androgen
receptor in LNCaP prostate cancer cells. Carcinogenesis.
22:409–414. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang G, Song L, Wang H and Xing N:
Quercetin synergizes with 2-methoxyestradiol inhibiting cell growth
and inducing apoptosis in human prostate cancer cells. Oncol Rep.
30:357–363. 2013.PubMed/NCBI
|
|
5
|
Sharmila G, Bhat FA, Arunkumar R, Elumalai
P, Raja Singh P, Senthilkumar K and Arunakaran J: Chemopreventive
effect of quercetin, a natural dietary flavonoid on prostate cancer
in in vivo model. Clin Nutr. 33:718–726. 2014. View Article : Google Scholar
|
|
6
|
Firdous AB, Sharmila G, Balakrishnan S,
RajaSingh P, Suganya S, Srinivasan N and Arunakaran J: Quercetin, a
natural dietary flavonoid, acts as a chemopreventive agent against
prostate cancer in an in vivo model by inhibiting the EGFR
signaling pathway. Food Funct. 5:2632–2645. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sharmila G, Athirai T, Kiruthiga B,
Senthilkumar K, Elumalai P, Arunkumar R and Arunakaran J:
Chemopreventive effect of quercetin in MNU and testosterone induced
prostate cancer of Sprague-Dawley rats. Nutr Cancer. 66:38–46.
2014. View Article : Google Scholar
|
|
8
|
Fleshner N: Defining high-risk prostate
cancer: current status. Can J Urol. (Suppl 1): 14–96.
2005.PubMed/NCBI
|
|
9
|
Hotte SJ and Saad F: Current management of
castrate-resistant prostate cancer. Curr Oncol. 17(Suppl 2):
S72–S79. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: TAX 327 Investigators: Docetaxel plus prednisone or
mitoxantrone plus prednisone for advanced prostate cancer. N Engl J
Med. 351:1502–1512. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Antonarakis ES and Eisenberger MA: Phase
III trials with docetaxel-based combinations for metastatic
castration-resistant prostate cancer: time to learn from past
experiences. J Clin Oncol. 31:1709–1712. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McKeage K: Docetaxel: a review of its use
for the first-line treatment of advanced castration-resistant
prostate cancer. Drugs. 72:1559–1577. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bischoff SC: Quercetin: potentials in the
prevention and therapy of disease. Curr Opin Clin Nutr Metab Care.
11:733–740. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Graefe EU, Wittig J, Mueller S, Riethling
AK, Uehleke B, Drewelow B, Pforte H, Jacobasch G, Derendorf H and
Veit M: Pharmacokinetics and bioavailability of quercetin
glycosides in humans. J Clin Pharmacol. 41:492–499. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Walle T, Otake Y, Walle UK and Wilson FA:
Quercetin glucosides are completely hydrolyzed in ileostomy
patients before absorption. J Nutr. 130:2658–2661. 2000.PubMed/NCBI
|
|
16
|
Russo GL, Russo M and Spagnuolo C: The
pleiotropic flavonoid quercetin: from its metabolism to the
inhibition of protein kinases in chronic lymphocytic leukemia. Food
Funct. 5:2393–2401. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim GT, Lee SH, Kim JI and Kim YM:
Quercetin regulates the sestrin 2-AMPK-p38 MAPK signaling pathway
and induces apoptosis by increasing the generation of intracellular
ROS in a p53-independent manner. Int J Mol Med. 33:863–869.
2014.PubMed/NCBI
|
|
18
|
Chan ST, Yang NC, Huang CS, Liao JW and
Yeh SL: Quercetin enhances the antitumor activity of trichostatin A
through upregulation of p53 protein expression in vitro and in
vivo. PLoS One. 8:e542552013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Piao S, Kang M, Lee YJ, Choi WS, Chun YS,
Kwak C and Kim HH: Cytotoxic effects of escin on human
castration-resistant prostate cancer cells through the induction of
apoptosis and G2/M cell cycle arrest. Urology. 84:982.e1–7. 2014.
View Article : Google Scholar
|
|
20
|
Mehta RG, Murillo G, Naithani R and Peng
X: Cancer chemo-prevention by natural products: how far have we
come? Pharm Res. 27:950–961. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu KC, Yen CY, Wu RS, Yang JS, Lu HF, Lu
KW, Lo C, Chen HY, Tang NY, Wu CC, et al: The roles of endoplasmic
reticulum stress and mitochondrial apoptotic signaling pathway in
quercetin-mediated cell death of human prostate cancer PC-3 cells.
Environ Toxicol. 29:428–439. 2014. View Article : Google Scholar
|
|
22
|
Samuel T, Fadlalla K, Mosley L, Katkoori
V, Turner T and Manne U: Dual-mode interaction between quercetin
and DNA-damaging drugs in cancer cells. Anticancer Res. 32:61–71.
2012.PubMed/NCBI
|
|
23
|
Kumar R, Verma V, Jain A, Jain RK,
Maikhuri JP and Gupta G: Synergistic chemoprotective mechanisms of
dietary phytoestrogens in a select combination against prostate
cancer. J Nutr Biochem. 22:723–731. 2011. View Article : Google Scholar
|
|
24
|
Noori-Daloii MR, Momeny M, Yousefi M,
Shirazi FG, Yaseri M, Motamed N, Kazemialiakbar N and Hashemi S:
Multifaceted preventive effects of single agent quercetin on a
human prostate adenocarcinoma cell line (PC-3): implications for
nutritional transcriptomics and multi-target therapy. Med Oncol.
28:1395–1404. 2011. View Article : Google Scholar
|
|
25
|
Haddad AQ, Venkateswaran V, Viswanathan L,
Teahan SJ, Fleshner NE and Klotz LH: Novel antiproliferative
flavonoids induce cell cycle arrest in human prostate cancer cell
lines. Prostate Cancer Prostatic Dis. 9:68–76. 2006. View Article : Google Scholar
|
|
26
|
Knowles LM, Zigrossi DA, Tauber RA,
Hightower C and Milner JA: Flavonoids suppress androgen-independent
human prostate tumor proliferation. Nutr Cancer. 38:116–122. 2000.
View Article : Google Scholar
|
|
27
|
Kampa M, Hatzoglou A, Notas G, Damianaki
A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas
E: Wine antioxidant polyphenols inhibit the proliferation of human
prostate cancer cell lines. Nutr Cancer. 37:223–233. 2000.
View Article : Google Scholar
|
|
28
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: Apoptosis: mechanisms and relevance in cancer. Ann
Hematol. 84:627–639. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jung YH, Heo J, Lee YJ, Kwon TK and Kim
YH: Quercetin enhances TRAIL-induced apoptosis in prostate cancer
cells via increased protein stability of death receptor 5. Life
Sci. 86:351–357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim YH, Lee DH, Jeong JH, Guo ZS and Lee
YJ: Quercetin augments TRAIL-induced apoptotic death: involvement
of the ERK signal transduction pathway. Biochem Pharmacol.
75:1946–1958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim YH and Lee YJ: TRAIL apoptosis is
enhanced by quercetin through Akt dephosphorylation. J Cell
Biochem. 100:998–1009. 2007. View Article : Google Scholar
|
|
32
|
Lee DH, Szczepanski M and Lee YJ: Role of
Bax in quercetin-induced apoptosis in human prostate cancer cells.
Biochem Pharmacol. 75:2345–2355. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Senthilkumar K, Elumalai P, Arunkumar R,
Banudevi S, Gunadharini ND, Sharmila G, Selvakumar K and Arunakaran
J: Quercetin regulates insulin like growth factor signaling and
induces intrinsic and extrinsic pathway mediated apoptosis in
androgen independent prostate cancer cells (PC-3). Mol Cell
Biochem. 344:173–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu R, Zhang Y, Ye X, Xue S, Shi J, Pan J
and Chen Q: Inhibition effects and induction of apoptosis of
flavonoids on the prostate cancer cell line PC-3 in vitro. Food
Chem. 138:48–53. 2013. View Article : Google Scholar
|
|
35
|
Wang P, Heber D and Henning SM: Quercetin
increased the anti-proliferative activity of green tea polyphenol
(-)-epigallocatechin gallate in prostate cancer cells. Nutr Cancer.
64:580–587. 2012. View Article : Google Scholar :
|
|
36
|
Vijayababu MR, Kanagaraj P, Arunkumar A,
Ilangovan R, Aruldhas MM and Arunakaran J: Quercetin-induced growth
inhibition and cell death in prostatic carcinoma cells (PC-3) are
associated with increase in p21 and hypophosphorylated
retinoblastoma proteins expression. J Cancer Res Clin Oncol.
131:765–771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shenouda NS, Zhou C, Browning JD, Ansell
PJ, Sakla MS, Lubahn DB and Macdonald RS: Phytoestrogens in common
herbs regulate prostate cancer cell growth in vitro. Nutr Cancer.
49:200–208. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Eder IE, Culig Z, Putz T, Nessler-Menardi
C, Bartsch G and Klocker H: Molecular biology of the androgen
receptor: from molecular understanding to the clinic. Eur Urol.
40:241–251. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Culig Z, Klocker H, Bartsch G and Hobisch
A: Androgen receptors in prostate cancer. Endocr Relat Cancer.
9:155–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Devlin HL and Mudryj M: Progression of
prostate cancer: multiple pathways to androgen independence. Cancer
Lett. 274:177–86. 2009. View Article : Google Scholar
|
|
41
|
Culig Z and Bartsch G: Androgen axis in
prostate cancer. J Cell Biochem. 99:373–381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yuan H, Young CY, Tian Y, Liu Z, Zhang M
and Lou H: Suppression of the androgen receptor function by
quercetin through protein-protein interactions of Sp1, c-Jun, and
the androgen receptor in human prostate cancer cells. Mol Cell
Biochem. 339:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ferruelo A, Romero I, Cabrera PM, Arance
I, Andrés G and Angulo JC: Effects of resveratrol and other wine
polyphenols on the proliferation, apoptosis and androgen receptor
expression in LNCaP cells. Actas Urol Esp. 38:397–404. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yuan H, Pan Y and Young CYF:
Overexpression of c-Jun induced by quercetin and resverol inhibits
the expression and function of the androgen receptor in human
prostate cancer cells. Cancer Lett. 213:155–163. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yuan HQ, Guo HF, He ML, Kong F, Hu XY,
Jiang AL, Xu X, Zhang JY and Charles YF: The roles of c-Jun and CBP
in the inhibitory effect of quercetin on prostate cancer cells. Yao
Xue Xue Bao. 41:819–824. 2006.In Chinese. PubMed/NCBI
|
|
46
|
Yuan H, Gong A and Young CY: Involvement
of transcription factor Sp1 in quercetin-mediated inhibitory effect
on the androgen receptor in human prostate cancer cells.
Carcinogenesis. 26:793–801. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Britton RG, Horner-Glister E, Pomenya OA,
Smith EE, Denton R, Jenkins PR, Steward WP, Brown K, Gescher A and
Sale S: Synthesis and biological evaluation of novel flavonols as
potential anti-prostate cancer agents. Eur J Med Chem. 54:952–958.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hsieh TC and Wu JM: Targeting CWR22Rv1
prostate cancer cell proliferation and gene expression by
combinations of the phytochemicals EGCG, genistein and quercetin.
Anticancer Res. 29:4025–4032. 2009.PubMed/NCBI
|
|
49
|
Morris JD, Pramanik R, Zhang X, Carey AM,
Ragavan N, Martin FL and Muir GH: Selenium- or quercetin-induced
retardation of DNA synthesis in primary prostate cells occurs in
the presence of a concomitant reduction in androgen-receptor
activity. Cancer Lett. 239:111–122. 2006. View Article : Google Scholar
|
|
50
|
Morgan TM, Koreckij TD and Corey E:
Targeted therapy for advanced prostate cancer: inhibition of the
PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets. 9:237–249. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Cohen MB and Rokhlin OW: Mechanisms of
prostate cancer cell survival after inhibition of AR expression. J
Cell Biochem. 106:363–371. 2009. View Article : Google Scholar
|
|
52
|
Baiz D, Pinder TA, Hassan S, Karpova Y,
Salsbury F, Welker ME and Kulik G: Synthesis and characterization
of a novel prostate cancer-targeted phosphatidylinositol-3-kinase
inhibitor prodrug. J Med Chem. 55:8038–8046. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Pratheeshkumar P, Budhraja A, Son YO, Wang
X, Zhang Z, Ding S, Wang L, Hitron A, Lee JC, Xu M, et al:
Quercetin inhibits angiogenesis mediated human prostate tumor
growth by targeting VEGFR-2 regulated AKT/mTOR/P70S6K signaling
pathways. PLoS One. 7:e475162012. View Article : Google Scholar
|
|
54
|
Yu PC, Gu SY, Bu JW and Du JL: TRPC1 is
essential for in vivo angiogenesis in zebrafish. Circ Res.
106:1221–1232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Potente M, Gerhardt H and Carmeliet P:
Basic and therapeutic aspects of angiogenesis. Cell. 146:873–887.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yancopoulos GD, Davis S, Gale NW, Rudge
JS, Wiegand SJ and Holash J: Vascular-specific growth factors and
blood vessel formation. Nature. 407:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Oh SJ, Kim O, Lee JS, Kim JA, Kim MR, Choi
HS, Shim JH, Kang KW and Kim YC: Inhibition of angiogenesis by
quercetin in tamoxifen-resistant breast cancer cells. Food Chem
Toxicol. 48:3227–3234. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Matei D, Schilder J, Sutton G, Perkins S,
Breen T, Quon C and Sidor C: Activity of 2 methoxyestradiol (Panzem
NCD) in advanced, platinum-resistant ovarian cancer and primary
peritoneal carcinomatosis: a Hoosier Oncology Group trial. Gynecol
Oncol. 115:90–96. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen Y, Li XX, Xing NZ and Cao XG:
Quercetin inhibits choroidal and retinal angiogenesis in vitro.
Graefes Arch Clin Exp Ophthalmol. 246:373–378. 2008. View Article : Google Scholar
|
|
61
|
Lee DH and Lee YJ: Quercetin suppresses
hypoxia-induced accumulation of hypoxia-inducible factor-1alpha
(HIF-1alpha) through inhibiting protein synthesis. J Cell Biochem.
105:546–553. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Shimada M, Hernandez-Gonzalez I,
Gonzalez-Robayna I and Richards JS: Paracrine and autocrine
regulation of epidermal growth factor-like factors in cumulus
oocyte complexes and granulosa cells: key roles for prostaglandin
synthase 2 and progesterone receptor. Mol Endocrinol. 20:1352–1365.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gioeli D, Mandell JW, Petroni GR, Frierson
HF Jr and Weber MJ: Activation of mitogen-activated protein kinase
associated with prostate cancer progression. Cancer Res.
59:279–284. 1999.PubMed/NCBI
|
|
64
|
Price DT, Della Rocca G, Guo C, Ballo MS,
Schwinn DA and Luttrell LM: Activation of extracellular
signal-regulated kinase in human prostate cancer. J Urol.
162:1537–1542. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shimada K, Nakamura M, Ishida E, Kishi M
and Konishi N: Roles of p38- and c-jun NH2-terminal kinase-mediated
pathways in 2-methoxyestradiol-induced p53 induction and apoptosis.
Carcinogenesis. 24:1067–1075. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Senthilkumar K, Arunkumar R, Elumalai P,
Sharmila G, Gunadharini DN, Banudevi S, Krishnamoorthy G, Benson CS
and Arunakaran J: Quercetin inhibits invasion, migration and
signalling molecules involved in cell survival and proliferation of
prostate cancer cell line (PC-3). Cell Biochem Funct. 29:87–95.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Cox ME, Gleave ME, Zakikhani M, Bell RH,
Piura E, Vickers E, Cunningham M, Larsson O, Fazli L and Pollak M:
Insulin receptor expression by human prostate cancers. Prostate.
69:33–40. 2009. View Article : Google Scholar
|
|
68
|
Nickerson T, Chang F, Lorimer D, Smeekens
SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and
LNCaP prostate cancer models to androgen independence is associated
with increased expression of insulin-like growth factor I (IGF-I)
and IGF-I receptor (IGF-IR). Cancer Res. 61:6276–6280.
2001.PubMed/NCBI
|
|
69
|
Vijayababu MR, Kanagaraj P, Arunkumar A,
Ilangovan R, Dharmarajan A and Arunakaran J: Quercetin induces
p53-independent apoptosis in human prostate cancer cells by
modulating Bcl-2-related proteins: a possible mediation by IGFBP-3.
Oncol Res. 16:67–74. 2006.PubMed/NCBI
|
|
70
|
Vijayababu MR, Arunkumar A, Kanagaraj P
and Arunakaran J: Effects of quercetin on insulin-like growth
factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and
induction of apoptosis in human prostate cancer cells. J Carcinog.
5:102006. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wang S, DeGroff VL and Clinton SK: Tomato
and soy poly-phenols reduce insulin-like growth factor-I-stimulated
rat prostate cancer cell proliferation and apoptotic resistance in
vitro via inhibition of intracellular signaling pathways involving
tyrosine kinase. J Nutr. 133:2367–2376. 2003.PubMed/NCBI
|
|
72
|
Bhat FA, Sharmila G, Balakrishnan S,
Arunkumar R, Elumalai P, Suganya S, Raja Singh P, Srinivasan N and
Arunakaran J: Quercetin reverses EGF-induced epithelial to
mesenchymal transition and invasiveness in prostate cancer (PC-3)
cell line via EGFR/PI3K/Akt pathway. J Nutr Biochem. 25:1132–1139.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Tang SN, Singh C, Nall D, Meeker D,
Shankar S and Srivastava RK: The dietary bioflavonoid quercetin
synergizes with epigallocathechin gallate (EGCG) to inhibit
prostate cancer stem cell characteristics, invasion, migration and
epithelial-mesenchymal transition. J Mol Signal. 5:142010.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ko CC, Chen YJ, Chen CT, Liu YC, Cheng FC,
Hsu KC and Chow LP: Chemical proteomics identifies heterogeneous
nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of
quercetin in its anti-cancer effects in PC-3 cells. J Biol Chem.
289:22078–22089. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ferruelo A, de Las Heras MM, Redondo C,
Ramón de Fata F, Romero I and Angulo JC: Wine polyphenols exert
antineoplasic effect on androgen resistant PC-3 cell line through
the inhibition of the transcriptional activity of COX-2 promoter
mediated by NF-κB. Actas Urol Esp. 38:429–437. 2014.In English and
Spanish. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Slusarz A, Shenouda NS, Sakla MS,
Drenkhahn SK, Narula AS, MacDonald RS, Besch-Williford CL and
Lubahn DB: Common botanical compounds inhibit the hedgehog
signaling pathway in prostate cancer. Cancer Res. 70:3382–3390.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Nair HK, Rao KV, Aalinkeel R, Mahajan S,
Chawda R and Schwartz SA: Inhibition of prostate cancer cell colony
formation by the flavonoid quercetin correlates with modulation of
specific regulatory genes. Clin Diagn Lab Immunol. 11:63–69.
2004.PubMed/NCBI
|
|
78
|
Bandyopadhyay S, Romero JR and
Chattopadhyay N: Kaempferol and quercetin stimulate
granulocyte-macrophage colony-stimulating factor secretion in human
prostate cancer cells. Mol Cell Endocrinol. 287:57–64. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Aalinkeel R, Bindukumar B, Reynolds JL,
Sykes DE, Mahajan SD, Chadha KC and Schwartz SA: The dietary
bioflavonoid, quercetin, selectively induces apoptosis of prostate
cancer cells by down-regulating the expression of heat shock
protein 90. Prostate. 68:1773–1789. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Jones EL, Zhao MJ, Stevenson MA and
Calderwood SK: The 70 kilodalton heat shock protein is an inhibitor
of apoptosis in prostate cancer. Int J Hyperthermia. 20:835–849.
2004. View Article : Google Scholar
|
|
81
|
Nakanoma T, Ueno M, Iida M, Hirata R and
Deguchi N: Effects of quercetin on the heat-induced cytotoxicity of
prostate cancer cells. Int J Urol. 8:623–630. 2001. View Article : Google Scholar
|
|
82
|
Asea A, Ara G, Teicher BA, Stevenson MA
and Calderwood SK: Effects of the flavonoid drug quercetin on the
response of human prostate tumours to hyperthermia in vitro and in
vivo. Int J Hyperthermia. 17:347–356. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Vijayababu MR, Arunkumar A, Kanagaraj P,
Venkataraman P, Krishnamoorthy G and Arunakaran J: Quercetin
downregulates matrix metalloproteinases 2 and 9 proteins expression
in prostate cancer cells (PC-3). Mol Cell Biochem. 287:109–116.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Chaudhary A and Willett KL: Inhibition of
human cytochrome CYP 1 enzymes by flavonoids of St. John’s wort.
Toxicology. 217:194–205. 2006. View Article : Google Scholar
|
|
85
|
Brusselmans K, Vrolix R, Verhoeven G and
Swinnen JV: Induction of cancer cell apoptosis by flavonoids is
associated with their ability to inhibit fatty acid synthase
activity. J Biol Chem. 280:5636–5645. 2005. View Article : Google Scholar
|
|
86
|
Huynh H, Nguyen TT, Chan E and Tran E:
Inhibition of ErbB-2 and ErbB-3 expression by quercetin prevents
transforming growth factor α (TGF-α)- and epidermal growth factor
(EGF)-induced human PC-3 prostate cancer cell proliferation. Int J
Oncol. 23:821–829. 2003.PubMed/NCBI
|
|
87
|
Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH
and Huynh H: Reduction of CWR22 prostate tumor xenograft growth by
combined tamoxifenquercetin treatment is associated with inhibition
of angiogenesis and cellular proliferation. Int J Oncol.
24:1297–1304. 2004.PubMed/NCBI
|
|
88
|
Wang P, Vadgama JV, Said JW, Magyar CE,
Doan N, Heber D and Henning SM: Enhanced inhibition of prostate
cancer xenograft tumor growth by combining quercetin and green tea.
J Nutr Biochem. 25:73–80. 2014. View Article : Google Scholar
|
|
89
|
Ma Z, Hung Nguyen T, Hoa Huynh T, Tien Do
P and Huynh H: Reduction of rat prostate weight by combined
quercetin-finasteride treatment is associated with cell cycle
deregulation. J Endocrinol. 181:493–507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Xiao ZP, Peng ZY, Peng MJ, Yan WB, Ouyang
YZ and Zhu HL: Flavonoids health benefits and their molecular
mechanism. Mini Rev Med Chem. 11:169–177. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Szliszka E and Krol W: The role of dietary
polyphenols in tumor necrosis factor-related apoptosis inducing
ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J
Cancer Prev. 20:63–69. 2011. View Article : Google Scholar
|
|
92
|
Leonarduzzi G, Testa G, Sottero B, Gamba P
and Poli G: Design and development of nanovehicle-based delivery
systems for preventive or therapeutic supplementation with
flavonoids. Curr Med Chem. 17:74–95. 2010. View Article : Google Scholar
|
|
93
|
Klingeler R, Hampel S and Büchner B:
Carbon nanotube based biomedical agents for heating, temperature
sensoring and drug delivery. Int J Hyperther. 24:496–505. 2008.
View Article : Google Scholar
|
|
94
|
Cirillo G, Vittorio O, Hampel S, Iemma F,
Parchi P, Cecchini M, Puoci F and Picci N: Quercetin nanocomposite
as novel anticancer therapeutic: improved efficiency and reduced
toxicity. Eur J Pharm Sci. 49:359–365. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Forbes AM, Lin H, Meadows GG and Meier GP:
Synthesis and anticancer activity of new flavonoid analogs and
inconsistencies in assays related to proliferation and viability
measurements. Int J Oncol. 45:831–842. 2014.PubMed/NCBI
|
|
96
|
Paliwal S, Sundaram J and Mitragotri S:
Induction of cancer-specific cytotoxicity towards human prostate
and skin cells using quercetin and ultrasound. Br J Cancer.
92:499–502. 2005.PubMed/NCBI
|
|
97
|
Lund L, Svolgaard N and Poulsen MH:
Prostate cancer: a review of active surveillance. Res Rep Urol.
6:107–112. 2014.PubMed/NCBI
|
|
98
|
Sakr WA, Haas GP, Cassin BF, Pontes JE and
Crissman JD: The frequency of carcinoma and intraepithelial
neoplasia of the prostate in young male patients. J Urol.
150:379–385. 1993.PubMed/NCBI
|
|
99
|
Thompson IM, Pauler DK, Goodman PJ, Tangen
CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford
ED, et al: Prevalence of prostate cancer among men with a
prostate-specific antigen level < or =4.0 ng per milliliter. N
Engl J Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Ting H, Deep G, Agarwal C and Agarwal R:
The strategies to control prostate cancer by chemoprevention
approaches. Mutat Res Fundam Mol Mech Mutagen. 760:1–15. 2014.
View Article : Google Scholar
|
|
101
|
Wang Z, Fan J, Liu M, Yeung S, Chang A,
Chow MS, Pon D and Huang Y: Nutraceuticals for prostate cancer
chemoprevention: from molecular mechanisms to clinical application.
Expert Opin Investig Drugs. 22:1613–1626. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Hsing AW, Tsao L and Devesa SS:
International trends and patterns of prostate cancer incidence and
mortality. Int J Cancer. 85:60–67. 2000. View Article : Google Scholar
|
|
103
|
Cook LS, Goldoft M, Schwartz SM and Weiss
NS: Incidence of adenocarcinoma of the prostate in Asian immigrants
to the United States and their descendants. J Urol. 161:152–155.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chaudhary A, Pechan T and Willett KL:
Differential protein expression of peroxiredoxin I and II by
benzo(a)pyrene and quercetin treatment in 22Rv1 and PrEC prostate
cell lines. Toxicol Appl Pharmacol. 220:197–210. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Gugler R, Leschik M and Dengler HJ:
Disposition of quercetin in man after single oral and intravenous
doses. Eur J Clin Pharmacol. 9:229–234. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Ferry DR, Smith A, Malkhandi J, Fyfe DW,
de Takats PG, Anderson D, Baker J and Kerr DJ: Phase I clinical
trial of the flavonoid quercetin: pharmacokinetics and evidence for
in vivo tyrosine kinase inhibition. Clin Cancer Res. 2:659–668.
1996.PubMed/NCBI
|
|
107
|
Egert S, Wolffram S, Bosy-Westphal A,
Boesch-Saadatmandi C, Wagner AE, Frank J, Rimbach G and Mueller MJ:
Daily quercetin supplementation dose-dependently increases plasma
quercetin concentrations in healthy humans. J Nutr. 138:1615–1621.
2008.PubMed/NCBI
|
|
108
|
Utesch D, Feige K, Dasenbrock J, Broschard
TH, Harwood M, Danielewska-Nikiel B and Lines TC: Evaluation of the
potential in vivo genotoxicity of quercetin. Mutat Res. 654:38–44.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Shoskes DA, Zeitlin SI, Shahed A and
Rajfer J: Quercetin in men with category III chronic prostatitis: a
preliminary prospective, double-blind, placebo-controlled trial.
Urology. 54:960–963. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Cialdella-Kam L, Nieman DC, Sha W, Meaney
MP, Knab AM and Shanely RA: Dose-response to 3 months of
quercetin-containing supplements on metabolite and quercetin
conjugate profile in adults. Br J Nutr. 109:1923–1933. 2013.
View Article : Google Scholar
|
|
111
|
McCann SE, Ambrosone CB, Moysich KB,
Brasure J, Marshall JR, Freudenheim JL, Wilkinson GS and Graham S:
Intakes of selected nutrients, foods, and phytochemicals and
prostate cancer risk in Western New York. Nutr Cancer. 53:33–41.
2005. View Article : Google Scholar : PubMed/NCBI
|
